Gilead/Galapagos, Intercept and Corbus trials could be hit by coronavirus spread: analyst

Analysts at RBC Capital Markets are warning that a host of biopharmas could see their ongoing phase 3 trials hit by the novel coronavirus, as early-stage trials are particularly under threat.

The analysts said that, in general, while the current coronavirus situation “appears relatively manageable” for its covered companies, “we do see potential for an escalating negative impact to some degree on uptake but greater extent on clinical trials.”